#United States #Burlingame #Generation Lab #biological age #SystemAge™

Revolutionizing Preventative Health with SystemAge™ 2.1

In a significant advancement for the field of preventative health diagnostics, Generation Lab has unveiled its latest platform, SystemAge™ 2.1. This innovative system is the first of its kind to provide sex-specific biological age assessments, distinguishing differences in aging processes between men and women. The launch was officially announced on June 25, 2026, and positions SystemAge as a groundbreaking tool in the evaluation of health and longevity.

The Importance of Sex-Specific Testing

Research spearheaded by Generation Lab has established that men and women experience aging through different biological timelines and response mechanisms. Traditional biological age tests often adopt a one-size-fits-all methodology, neglecting the unique factors that influence aging in each sex. Alina Su, CEO and Co-Founder, emphasizes that with SystemAge 2.1, they bridge this gap by offering tailored analyses that can lead to more effective health interventions. The measurements now take into account the distinct biological drivers at play, making it a powerful tool for both healthcare professionals and patients aiming to optimize their health.

What’s New in SystemAge™ 2.1?

The improvements introduced with SystemAge™ 2.1 are substantial and multiple:

• - Dedicated Testing for Each Sex: This release provides male and female-specific assessments across 21 organ systems, allowing for more precise health evaluations.
• - Expanded Organ Coverage: The system now includes new insights into skin, connective tissue, reproductive health, and mitochondrial function—critical areas often overlooked in general assessments.
• - Longitudinal Aging Trends: Users can track how their biological age evolves over time, enabling proactive health management and intervention strategies.
• - Accelerated Aging Detection: The platform is capable of identifying signs of accelerated aging in specific organs long before clinical symptoms arise.
• - Treatment Efficacy Tracking: Healthcare providers can monitor the effectiveness of various treatments, including NAD+ therapies, peptide protocols, and lifestyle changes on an organ-by-organ basis.
• - Personalized Longevity Protocols: In partnership with healthcare providers, users will receive customized plans designed to enhance their longevity based on individual aging profiles.

Breakthrough Science: Understanding Biological Noise

At the heart of the SystemAge™ 2.1 platform is the concept of Biological Noise. Unlike traditional methods, which often rely on methylation clocks that have shown variability in diverse populations, Generation Lab's approach measures fluctuations in DNA methylation patterns across age-dysregulated cytosines. This method offers the most accurate signal of biological aging to date, as described in their study published in Aging: The Journal of Clinical and Experimental Research on Aging. This innovative technique has tested and validated successfully against both healthy and diseased cohorts, consistently outperforming other industry standards in terms of accuracy and clinical applicability.

Global Reach and Immediate Availability

SystemAge™ has already made its mark globally, being implemented in over 750 clinics across 18 countries. These include esteemed institutions such as Boulder Longevity Institute and Eterna Health. Users have reported remarkable results that include an average biological age reduction of over 5 years following stem cell treatments and substantial immune system rejuvenation through therapeutic plasma exchange.

As of now, SystemAge™ 2.1 is available for immediate use in existing clinics that partner with Generation Lab. New clinics interested in collaboration can easily join through Generation Lab’s onboarding program. For those wanting to explore the possibilities of this revolutionary diagnostic tool, the company’s website offers an opportunity to request a demonstration.

About Generation Lab

Founded by Prof. Irina Conboy, a pioneer in longevity research, Generation Lab is at the forefront of aging diagnostics. It boasts the world's largest database of human biological aging data, with over 600 million epigenetic datasets. The company is backed by notable investors including Accel and Samsung. With SystemAge™, Generation Lab aims to empower individuals and healthcare providers with the knowledge to combat aging effectively, offering a tangible solution to enhancing healthspan alongside lifespan.

In summary, the launch of SystemAge™ 2.1 marks an exciting new chapter in the realm of health diagnostics, reflecting a deeper understanding of how aging operates differently in men and women, and paving the way for more personalized healthcare solutions.